-
公开(公告)号：WO2009099545A1
公开(公告)日：2009-08-13
申请号：PCT/US2009/000568
申请日：2009-01-29
Applicant: ABBOTT LABORATORIES , ARGIRIADI, Maria A. , BORHANI, David W. , XIANG, Tao , WU, Chengbin , GHAYUR, Tariq
Inventor： ARGIRIADI, Maria A. , BORHANI, David W. , XIANG, Tao , WU, Chengbin , GHAYUR, Tariq
IPC: A61K39/395
CPC classification number: C30B29/58 , C07K1/306 , C07K16/244 , C07K2299/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2317/92 , C30B7/00
Abstract: The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes.
Abstract translation: 本发明提供结晶抗体及其片段以及由此制备的晶体的方法。 更具体地，本发明提供了将人抗体和非人Fab片段单独或与其靶配体共晶结晶的方法。 例如，提供了包含结合IL-18的抗体125-2H的鼠Fab片段或抗体ABT-325的人Fab片段的结晶以及结合于鼠Fab片段的共晶体 到IL-18。 ABT-325和125-2H在组合位点特征和结构上有显着差异，从而说明了它们在不同表位同时结合IL-18的能力。
-
公开(公告)号：WO2008121301A1
公开(公告)日：2008-10-09
申请号：PCT/US2008/004006
申请日：2008-03-27
Applicant: ABBOTT LABORATORIES , BORHANI, David W. , FRAUNHOFER, Wolfgang , KRAUSE, Hans-Juergen , KOENIGSDORFER, Anette , WINTER, Gerhard , GOTTSCHALK, Stefan
Inventor： BORHANI, David W. , FRAUNHOFER, Wolfgang , KRAUSE, Hans-Juergen , KOENIGSDORFER, Anette , WINTER, Gerhard , GOTTSCHALK, Stefan
CPC classification number: C07K16/244 , A61K39/39591 , C07K2299/00 , C30B7/00 , Y02A50/401
Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
Abstract translation: 本发明涉及用于结晶能够以工业规模生产抗体的抗-hIL-12抗体的分批结晶方法，根据该方法获得的抗体晶体，含有晶体的组合物，以及使用晶体和组合物的方法 。
-
公开(公告)号：WO2009020654A1
公开(公告)日：2009-02-12
申请号：PCT/US2008/009549
申请日：2008-08-08
Applicant: ABBOTT LABORATORIES , FRAUNHOFER, Wolfgang , BORHANI, David W. , WINTER, Gerhard , GOTTSCHALK, Stefan
Inventor： FRAUNHOFER, Wolfgang , BORHANI, David W. , WINTER, Gerhard , GOTTSCHALK, Stefan
IPC: A61K39/395
CPC classification number: C07K16/241 , A61K2039/505 , C07K1/306 , C07K2299/00 , C07K2317/14 , C07K2317/54 , C07K2317/76 , C30B29/58 , Y02A50/388
Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.
Abstract translation: 本发明涉及用于结晶抗人TNFα（hTNFα）抗体的分批结晶方法和允许以工业规模生产所述抗体的抗体片段; 控制抗体晶体大小的方法，例如抗hTNFα抗体片段的晶体，含有所述晶体的组合物以及使用所述晶体和组合物的方法。
-
公开(公告)号：WO2007117465A2
公开(公告)日：2007-10-18
申请号：PCT/US2007/008307
申请日：2007-04-02
Applicant: ABBOTT LABORATORIES , ERICSSON, Anna M. , BURCHAT, Andrew , FRANK, Kristine E. , CALDERWOOD, David J. , ABBOTT, Lily K. , ARGIRIADI, Maria A. , BORHANI, David W. , CUSACK, Kevin P. , DIXON, Richard W. , GORDON, Thomas D. , MULLEN, Kelly D. , TALANIAN, Robert V. , WU, Xiaoyun , ZHANG, Xiaolei , WANG, Lu X. , LI, Biqin , BARBERIS, Claude E. , WISHART, Neil
Inventor： ERICSSON, Anna M. , BURCHAT, Andrew , FRANK, Kristine E. , CALDERWOOD, David J. , ABBOTT, Lily K. , ARGIRIADI, Maria A. , BORHANI, David W. , CUSACK, Kevin P. , DIXON, Richard W. , GORDON, Thomas D. , MULLEN, Kelly D. , TALANIAN, Robert V. , WU, Xiaoyun , ZHANG, Xiaolei , WANG, Lu X. , LI, Biqin , BARBERIS, Claude E. , WISHART, Neil
IPC: A61K31/5377
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract translation: 式（I）的新型化合物或其药学上可接受的盐，前体药物和式（I）的生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。
-
Patent Agency Ranking
公开(公告)号：EP2247310A1
公开(公告)日：2010-11-10
申请号：EP09708386.9
申请日：2009-01-29
Applicant: Abbott Laboratories
Inventor： ARGIRIADI, Maria A. , BORHANI, David W. , XIANG, Tao , WU, Chengbin , GHAYUR, Tariq
IPC: A61K39/395
CPC classification number: C30B29/58 , C07K1/306 , C07K16/244 , C07K2299/00 , C07K2317/21 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2317/92 , C30B7/00
Abstract: The invention provides methods of crystallizing antibodies and fragments thereof as well as crystals produced thereby. More particularly, the invention provides methods of crystallizing human and non-human Fab fragments of antibodies, either alone or as co-crystals with their target ligand. For example, a crystal comprising a murine Fab fragment of the antibody 125-2H or a human Fab fragment of the antibody ABT-325, which bind to IL-18, are provided as well as a co-crystal of a murine Fab fragment bound to IL-18. ABT-325 and 125-2H differ significantly in combining site character and architecture, thus explaining their ability to bind IL-18 simultaneously at distinct epitopes.
-
公开(公告)号：EP2185201A1
公开(公告)日：2010-05-19
申请号：EP08795162.0
申请日：2008-08-08
Applicant: Abbott Laboratories
Inventor： FRAUNHOFER, Wolfgang , BORHANI, David W. , WINTER, Gerhard , GOTTSCHALK, Stefan
IPC: A61K39/395
CPC classification number: C07K16/241 , A61K2039/505 , C07K1/306 , C07K2299/00 , C07K2317/14 , C07K2317/54 , C07K2317/76 , C30B29/58 , Y02A50/388
Abstract: The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions.
-
公开(公告)号：EP2142565A1
公开(公告)日：2010-01-13
申请号：EP08742311.7
申请日：2008-03-27
Applicant: ABBOTT LABORATORIES
Inventor： BORHANI, David W. , FRAUNHOFER, Wolfgang , KRAUSE, Hans-Juergen , KOENIGSDORFER, Anette , WINTER, Gerhard , GOTTSCHALK, Stefan
CPC classification number: C07K16/244 , A61K39/39591 , C07K2299/00 , C30B7/00 , Y02A50/401
Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.
-
公开(公告)号：EP2068869A2
公开(公告)日：2009-06-17
申请号：EP07870771.8
申请日：2007-10-05
Applicant: ABBOTT LABORATORIES
Inventor： BORHANI, David W. , CALDERWOOD, David J. , FRANK, Kristine E. , DAVIS, Heather M. , JOSEPHSOHN, Nathan S. , SKINNER, Barbara S.
IPC: A61K31/41 , C07D257/04
CPC classification number: C07D498/04 , C07D513/04 , C07D519/00
Abstract: The present invention is directed to novel compounds of formula (I) wherein the variables are as defined herein. The compounds of formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.
-
公开(公告)号：EP2001480A2
公开(公告)日：2008-12-17
申请号：EP07754773.5
申请日：2007-04-02
Applicant: ABBOTT LABORATORIES
Inventor： ERICSSON, Anna M. , BURCHAT, Andrew , FRANK, Kristine E. , CALDERWOOD, David J. , ABBOTT, Lily K. , ARGIRIADI, Maria A. , BORHANI, David W. , CUSACK, Kevin P. , DIXON, Richard W. , GORDON, Thomas D. , MULLEN, Kelly D. , TALANIAN, Robert V. , WU, Xiaoyun , ZHANG, Xiaolei , WANG, Lu X. , LI, Biqin , BARBERIS, Claude E. , WISHART, Neil
IPC: A61K31/5377
CPC classification number: C07D487/04 , C07D403/12 , C07D403/14 , C07D409/04 , C07D409/14
Abstract: Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.
Abstract translation: 式（I）的新化合物或其式（I）的药用盐，前药和生物活性代谢物，其中取代基如本文所定义，其可用作治疗剂。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.027 seconds)
